Vol. 5 No. 9 (2025)
Reimbursement Reviews

Pembrolizumab (Keytruda)

Published September 5, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Pembrolizumab (Keytruda), 100 mg/4 mL vial, IV injection.
  • Indication: Pembrolizumab is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel, and then continued as monotherapy.